Keynote lecture: psoriasis update

References

• Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA296, 1735–1741 (2006).
   PubMed Web of Science ®Google Scholar
• Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur. J. Epidemiol.19, 225–230 (2004).
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch. Dermatol.143, 1493–1499 (2007).
   PubMed Web of Science ®Google Scholar
• Reich K, Krüger K, Augustin M. Epidemiology and clinical pattern of arthritis in a daily practice psoriasis population – a prospective interdisciplinary observational study in 1511 patients. Presented at: the Annual General Meeting of the European Academy of Dermatology and Venereology. Rhodes, Greece, 5 October 2006 (Abstract FC01.4).
   Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine use. Clin. Exp. Dermatol.19, 210–216 (1994).
   PubMed Web of Science ®Google Scholar
• Hongbo Y, Thomas CL, Harrison MA et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J. Invest. Dermatol.125, 659–664 (2005).
   PubMed Web of Science ®Google Scholar
• Krüger K, Augustin M, Rauch C, Reich K. Prevalence and clinical manifestation of arthritis in a daily practice psoriasis population – a prospective observational epidemiological study in Germany. Ann. Rheum. Dis.65(Suppl. II), 531 (2006).
   Google Scholar
• Smith CH, Anstey AV, Barker JN et al.; British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br. J. Dermatol.153, 486–497 (2005).
   PubMed Web of Science ®Google Scholar
• Nast A, Kopp I, Augustin M et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch. Dermatol. Res.299, 111–138 (2007).
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J. Am. Acad. Dermatol.58, 826–850 (2008).
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet366, 1367–1374 (2005).
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br. J. Dermatol.154, 1161–1168 (2006).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol.51, 534 (2004).
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M et al. A global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy and effect of dose reduction. Br. J. Dermatol.152, 1304–1312 (2005).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med.349, 14–22 (2003).
   Google Scholar
• Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA290, 3073–3080 (2003).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med.349, 2004–2013 (2004).
   Google Scholar
• Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate to severe plaque psoriasis. J. Am. Acad. Dematol.56, 31.E1–15 (2007).
   PubMed Web of Science ®Google Scholar
• Leonardi C, Menter A, Hamilton T et al. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br. J. Dermatol.158(5), 1107–1116 (2008).
   PubMed Web of Science ®Google Scholar
• Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br. J. Dermatol.156, 945–950 (2007).
   PubMed Web of Science ®Google Scholar
• Rich P, Griffiths CEM, Reich K et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J. Am. Acad. Dermatol.58, 224–231 (2007).
   PubMedGoogle Scholar
• Reich K, Nestle FO, Wu Y et al. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur. J. Dermatol.17, 381–386 (2007).
   PubMed Web of Science ®Google Scholar
• Philipp S, Hauptmann P, Popp G et al. Patients with moderate to severe disease show rapid improvement in the quality of life during infliximab therapy, independently of severity of disease and previous systemic therapies (P437). Presented at: 5th EADV Spring Symposium. Istanbul, Turkey, 11–25 May 2008.
   Google Scholar
• St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum.50, 3432–3443 (2004).
   PubMed Web of Science ®Google Scholar
• Goekopp-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum.52, 3381–3390 (2005).
   PubMedGoogle Scholar
• van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann. Rheum. Dis.66, 1356–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Reich K, Hüffmeier U, König IR et al. TNF polymorphisms in psoriasis: association with psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum.56, 2056–2064 (2007).
   PubMedGoogle Scholar
• Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled Phase III trial. J. Am. Acad. Dermatol.58, 106–115 (2008).
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M et al.; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet371, 1675–1684 (2008).
   PubMed Web of Science ®Google Scholar
• van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum.56, 2129–2134 (2007).
   PubMed Web of Science ®Google Scholar